Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 08, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details specific share movements within the SmithKline Beecham Employee Benefit Trust ("the Trust") on August 04, 2005:
- 274 Ordinary shares were sold on behalf of a participant in the GlaxoSmithKline Annual Investment Plan at a price of GBP 13.4036.
- 895 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on strategy, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J Heslop holds an interest in the fund shares similarly to other beneficiaries.
Investor Verification Points
- Verify the total volume of shares held by the SmithKline Beecham Employee Benefit Trust to assess the significance of the reported transactions.
- Confirm the current share price relative to the transaction price of GBP 13.4036 to understand market context.
- Review the full list of Directors and Persons Discharging Managerial Responsibility to identify other potential connected person transactions.